Three US Fingolimod Approvals Raise Legal Stakes
Approvals for Biocon, HEC and Sun Pharma
The first three FDA approvals for generic fingolimod generics come amid ongoing legal uncertainty over Novartis’ Gilenya blockbuster multiple sclerosis treatment.
You may also be interested in...
Having had a very fruitful year in terms of regulatory approvals, the Swiss major will reveal how successful its new products have been commercially. Of particular interest will be the performance of eye drug Beovu as it takes on Bayer's rival Eylea.
Teva and Pharmascience are going head-to-head in a battle to capture the market for generic Gilenya fingolimod capsules in Canada.
New Sandoz chief Richard Saynor says the division is undergoing a transformation towards building a generics-focused business. Meanwhile, the company is still waiting to close the sale of its US oral-dose and dermatology operations to Aurobindo.